RIV

RIVERNORTH OPPORTUNITIES FUND, INC.

NYSE · CIK 0001501072
$11.45 -0.09%
Vol
Inst. Holders3 funds
Inst. Value$27.2M
Inst. Activity1 buys / 0 sells
Exchange NYSE·CIK 0001501072·Prev Close $11.46

Recent Activity

Inst.
BANK OF AMERICA CORP — DOUBLED
311,461 shares ($3.7M)
Inst.
BANK OF AMERICA CORP — ADD
47,442 shares ($581.6K)

Top Institutional Holders

FundValueMove
MORGAN STANLEY$20.3M
BANK OF AMERICA CORP$3.7MDOUBLED
WELLS FARGO & COMPANY/MN$3.2M
3 institutional holders with $27.2M total value (2,320,811 shares) as of 2025-Q4. Top holders: MORGAN, BANK, WELLS. Net buying activity: 1 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1MORGAN STANLEY1,732,561$20.3M74.7%
2BANK OF AMERICA CORP /DE/311,461$3.7M13.4%DOUBLED +562.9%
3WELLS FARGO & COMPANY/MN276,789$3.2M11.9%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
BANK OF AMERICA CORP /DE/DOUBLED46,988311,461+562.9%$3.7M2025-Q4
BANK OF AMERICA CORP /DE/ADD25,01147,442+89.7%$581.6K2025-Q2
UBS Group AGTRIM37,94620,282-46.6%$239.1K2025-Q1
UBS Group AGADD25,50237,946+48.8%$436.0K2024-Q4

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
$0.00 $0.00 $0.00 $0.0B
Next Q
$0.00 $0.00 $0.00 $0.0B
Current FY
$0.00 $0.00 $0.00 $0.0B
Next FY
$0.00 $0.00 $0.00 $0.0B

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.